Considerations in using human pluripotent stem cell–derived pancreatic beta cells to treat type 1 diabetes

Wei, Tan; Lau, Hwee Hui; Tan, Nguan Soon; Khoo, Chin Meng; Teo, Adrian Kee Keong

doi:10.1016/b978-0-12-822229-4.00012-7

Cited by 3 publications

(5 citation statements)

References 122 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To address the pitfalls of PED-Direct's membrane permeability, ViaCyte created another encapsulated device with the capacity to protect against the immune system called PEC-Encap (VC-01) (Figure 3). PEC-Encap consists of an Encaptra membrane that shields the device from immune cells, eliminating the need for immunosuppressant drugs [20]. In addition to protecting the stem cells from the immune response, the encapsulated device also allows for the exchange of nutrients and wastes [20].…”

Section: Stem Cell Encapsulated Devicesmentioning

confidence: 99%

“…PEC-Encap consists of an Encaptra membrane that shields the device from immune cells, eliminating the need for immunosuppressant drugs [20]. In addition to protecting the stem cells from the immune response, the encapsulated device also allows for the exchange of nutrients and wastes [20]. The first PEC-Encap clinical trial began in 2014 to determine the safety and efficacy of immune protective devices in treating T1D [22].…”

Section: Stem Cell Encapsulated Devicesmentioning

confidence: 99%

See 1 more Smart Citation

Stem Cell Therapy For Type 1 Diabetes

Schweitzer,

Gallicchio

2023

JSCR

View full text Add to dashboard Cite

Type 1 diabetes is an increasingly widespread autoimmune disorder that destroys the insulin-producing cells of the pancreas. Without insulin, the cells cannot insert glucose transporters into their membrane and blood sugar subsequently rises. The effects of type 1 diabetes can develop into various life-threatening conditions including heart attacks and strokes. Insulin therapy is required for type 1 diabetics, but its short-lived effects are less than ideal and often decrease quality of life. Stem cells offer a long-term solution with their ability to differentiate into insulin-producing beta cells and modulate the immune system. They can be injected directly into the body or implanted in encapsulated devices. Regardless of the technique, stem cells can restore insulin production in the body and offer a potential cure for type 1 diabetes. Stem cell therapy has a list of benefits, but the advanced technology will inevitably come with a high price tag, contributing to the increasingly inaccessible treatment options for type 1 diabetes. Should future success convince the FDA to approve its clinical use and convince insurance to cover the procedure, the long-term solution of stem cell therapy might replace insulin injections forever.

show abstract

Section: Stem Cell Encapsulated Devicesmentioning

confidence: 99%

Section: Stem Cell Encapsulated Devicesmentioning

confidence: 99%

Stem Cell Therapy For Type 1 Diabetes

Schweitzer,

Gallicchio

2023

JSCR

View full text Add to dashboard Cite

show abstract

“…Existing challenges, such as tumorigenic potential, functional immaturity, and achieving full compliance with current good manufacturing practice (cGMP) regulations enforced by the regulators will need to be overcome. 132 The functionally less-mature hPSC-derived b-like cells would also mean that a higher islet mass and/or more infusions will be required for a single transplantation. Nevertheless, these functionally less-mature b-like cells have been shown to restore normoglycemia in diabetic models.…”

Section: Human Pluripotent Stem Cell (Hpsc)-derived Islet-like Cells For Transplantationmentioning

confidence: 99%

“…However, some considerations with this approach include the following: (1) the genetic background of hiPSCs should not contain diabetes-associated gene variant(s) that can cause inferior b cell function, (2) adult somatic cells used to generate hiPSCs may have accumulated unknown mutations throughout life that can affect the quality of differentiated b cells, and (3) every different hiPSC line may require customized optimization for differentiation and regulatory approval for GMP production. 132,135,136 Alternatively, should the approach Review of using allogeneic hiPSC-derived b cell transplantation be adopted, then there is a need to devise strategies to avoid autoimmune rejections in T1D.…”

Section: Human Pluripotent Stem Cell (Hpsc)-derived Islet-like Cells For Transplantationmentioning

confidence: 99%

Charting the next century of insulin replacement with cell and gene therapies

Lau

Shen

Lickert

et al. 2021

Med

Self Cite

View full text Add to dashboard Cite

The discovery of insulin a century ago changed the lives of millions of individuals suffering from diabetes, paving the way for long-term survival. While the availability of recombinant insulin for hormone replacement therapy has served extremely well to help control blood glucose in diabetes, there remains significant room for further improvements for an ultimate ''cure'' for diabetes patients. In this review, we celebrate the 100th anniversary of the discovery of insulin and consolidate the key milestones and advances in the development of recombinant human insulin. We then summarize recent and current technological developments in terms of insulin gene-and cell-replacement therapies that are promising in greater therapeutic potential. We envision that the next era of insulin replacement therapies will effectively treat diabetes and serve our patients even better for the next century to come.

show abstract

“…4). Promoter regions were amplified and subjected to restriction enzyme digestion for ligation into luciferase vector.…”

mentioning

confidence: 99%

Dissecting the role of diabetes-associated PAX4 polymorphisms in modulating pancreatic beta cell development and function

Lau¹

View full text Add to dashboard Cite

It is a great learning journey and great pleasure working with everyone.I thank all members of the AT lab for both the scientific and mental support all these while.Together we have grown to become better versions of ourselves, have transited into a more competent scientist over the years. It is a great joy to work alongside with everyone. I am truly grateful for the bond we fostered and looking forward to more friendships in the coming years.I would like to take this opportunity to thank Dr. Adrian Teo again, for being a great mentor, he has helped me tremendously in this journey of self-discovery. I thank Dr. Adrian Teo for giving me challenges that I never thought I would be able to overcome, and at the same time, showing me ways to clear obstacles that get in the way. I am forever grateful for the trainings he gave, and always pushing me to do better each time. I look forward to working on more projects together.Lastly, I thank my parents and two sisters, for giving me comfort when things get rough. I thank my husband for embracing this journey with me, supporting me in all possible ways. His strong belief in me has given me the strength to continue to strive harder in life. Table of Contents ContentsStatement of Originality .

show abstract

Considerations in using human pluripotent stem cell–derived pancreatic beta cells to treat type 1 diabetes

Cited by 3 publications

References 122 publications

Stem Cell Therapy For Type 1 Diabetes

Stem Cell Therapy For Type 1 Diabetes

Charting the next century of insulin replacement with cell and gene therapies

Dissecting the role of diabetes-associated PAX4 polymorphisms in modulating pancreatic beta cell development and function

Contact Info

Product

Resources

About